1. American Heart Association Heart Disease and Stroke Statistics. (2010). Update at-a-glance. Dallas: American Heart Association.
2. Dib, N., Menasche, P., Bartunek, J., et al. (2010). Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. Journal of the American College of Cardiology Cardiovascular Interventions, 3, 265–75.
3. Hou, D., Youssef, E. A., Brinton, T. J., et al. (2005). Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation, 112(Suppl I), I150–I156.
4. Sherman, W., Martens, T. P., Viles-Gonzalez, J. F., & Siminiak, T. (2006). Catheter-based delivery of cells to the heart. Nature Clinical Practice. Cardiovascular Medicine, 3(Suppl 1), S58–S60.
5. Biocardia (2005) A Phase I/II, Randomized, double-blinded, placebo-controlled study of the safety and efficacy of transendocardial injection of autologous human cells (bone marrow or mesenchymal) in patients with chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction. http://clinicaltrials.gov/archive/NCT00102128/2005_12_08 . Accessed 9 February 2010.